Manager × security

DAFNA Capital Management LLC XENE holdings history

Who else holds this security? →

XENON PHARMACEUTICALS INC · CUSIP 98420N105 · CIK 1389933

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, DAFNA Capital Management LLC reported 250.77K XENE (shares), valued at $15.14M, or 2.89% of its reported non-derivative portfolio. Filed 2026-08-14.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
2.89%
Shares
250.77K
250,772
Reported value
$15.14M
USD

Shares unchanged; reported value increased 3.80%, and weight changed -0.43 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20262.89%250,772SEC filing ↗Filed Aug 14, 2026
Q1 20263.32%250,772SEC filing ↗Filed May 15, 2026
Q4 20253.00%287,939SEC filing ↗Filed Feb 17, 2026
Q3 20252.86%287,939SEC filing ↗Filed Nov 14, 2025
Q2 20252.49%287,939SEC filing ↗Filed Aug 14, 2025
Q1 20252.60%273,739SEC filing ↗Filed May 15, 2025
Q4 20242.73%273,739SEC filing ↗Filed Feb 14, 2025
Q3 20242.55%273,739SEC filing ↗Filed Nov 14, 2024
Q2 20242.55%273,739SEC filing ↗Filed Aug 14, 2024
Q1 20242.68%273,739SEC filing ↗Filed May 15, 2024
Q4 20233.05%276,739SEC filing ↗Filed Feb 14, 2024

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q4 20233.05%276,739$12.75MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Feb 14, 2024
Q1 20242.68%273,739$11.78MShares decreased 1.08%; reported value decreased 7.55%, and weight changed -0.37 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 20242.55%273,739$10.67MShares unchanged; reported value decreased 9.43%, and weight changed -0.13 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2024
Q3 20242.55%273,739$10.78MShares unchanged; reported value increased 0.97%, and weight changed +0.00 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 20242.73%273,739$10.73MShares unchanged; reported value decreased 0.43%, and weight changed +0.18 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 20252.60%273,739$9.18MShares unchanged; reported value decreased 14.41%, and weight changed -0.13 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2025
Q2 20252.49%287,939$9.01MShares increased 5.19%; reported value decreased 1.87%, and weight changed -0.11 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2025
Q3 20252.86%287,939$11.56MShares unchanged; reported value increased 28.27%, and weight changed +0.37 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2025
Q4 20253.00%287,939$12.91MShares unchanged; reported value increased 11.63%, and weight changed +0.14 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 20263.32%250,772$14.58MShares decreased 12.91%; reported value increased 12.99%, and weight changed +0.32 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 20262.89%250,772$15.14MShares unchanged; reported value increased 3.80%, and weight changed -0.43 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2026
DAFNA Capital Management LLC · XENON PHARMACEUTICALS INC

Take these holdings further.

This page includes 11 of 11 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1389933","quarter":"2026Q2","cusip":"98420N105"}

get_institutional_manager_history
{"cik":"1389933","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.